plc (NASDAQ: ALKS) today announced completion of patient enrollment
in a phase 2 study of ALKS 3831, an investigational, novel, oral,
broad-spectrum atypical antipsychotic medicine in development for the
treatment of schizophrenia.
for Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic investment picks